Latest news with #Synthego
Associated Press
2 days ago
- Business
- Associated Press
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
REDWOOD CITY, Calif., June 12, 2025 /PRNewswire/ -- Synthego, a pioneering CRISPR Solutions provider, is pleased to announce that the US Court of Appeals for the Federal Circuit has upheld an earlier ruling invalidating patents held by Agilent Technologies, Inc. See the ruling here. In the original case, ruling dated May 17, 2023, the Patent Trial and Appeal Board (PTAB) ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos. 10,337,001 (the '001 patent) and 10,900,034 (the '034 patent) in the Inter Partes Review before the PTAB. The PTAB's original decision invalidated all claims of the Agilent patents, which were directed to guide RNAs having at least one 2'-O-methyl modification ('034 patent) and guide RNAs having certain modifications within 5 nucleotides of their 5' and/or 3' end ('001) patent), as well as methods of using such modified guide RNAs for CRISPR gene editing. 'This critical decision, affirming that Agilent's claims on chemically modified gRNAs are unpatentable, keeps the path clear for broader innovation and advancement in the CRISPR therapeutics market,' said Craig Christianson, CEO of Synthego. 'Synthego will continue our focus on supporting our clients' efforts to enhance human health with curative cell and gene therapies.' Synthego continues to support innovation in the field of CRISPR-enabled research and therapeutics, this affirmation enables researchers and therapeutic developers to continue to drive successful patient outcomes. About Synthego Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. View original content to download multimedia: SOURCE Synthego
Bloomberg
06-05-2025
- Business
- Bloomberg
Gene-Editor Synthego Files Bankruptcy With Plans to Sell Itself to Lenders
Synthego Corp., which makes gene-editing tools for drug developers and other researchers, filed for bankruptcy with plans to sell itself to its main lender, an affiliate of private equity firm Perceptive Advisors. Perceptive Credit Holdings III would trade as much as $85 million in debt for ownership of Synthego, unless a higher offer comes in, the company said in a proposal filed Monday in federal court in Wilmington, Delaware. Perceptive manages about $8 billion that is largely focused on health-care technology.
